Frightening study! Johnson & Johnson vaccine recipients almost 4 times more likely to get blood clots!


Johnson & Johnson COVID vaccine recipients are nearly 4 times more likely to get blood clots, a just-completed study found!

New study with hefty results

.

A new study conducted in Minnesota has found that citizens who received Johnson & Johnson’s COVID-19 vaccine have an increased risk of developing blood clots.

The Mayo Clinic study found that recipients of Johnson & Johnson’s vaccine, officially known as “Janssen,” in Olmsted County, Minnesota, were about 3.7 times more likely to develop a certain type of blood clot in the brain. Case counts from Feb. 28 to May 7, 2021, were compared to pre-pandemic levels that occurred from Jan. 1, 2001, to Dec. 31, 2015.

Other studies were not as clear

.

Previous studies on this topic, such as the Mayo Clinic study, have not produced conclusive results. Despite the worrisome data, it noted that the number of recipients who develop blood clots is still statistically rare and “considered in the context of the vaccine’s effectiveness in preventing COVID-19.”

The study found that the risk of developing blood clots was significantly higher in women. Female recipients of the Johnson & Johnson vaccine observed in the study were about 5.1 times more likely to experience the side effect than they were before the pandemic. Of all the populations defined for the study, the risk was highest among women between 40 and 49 years of age, followed by women between 30 and 39 years of age.

However, it was also emphasized that “the absolute risk of side effects is still low.”

“It was surprising that women in particular (especially 30- to 49-year-old women) had a higher risk of (cerebral venous sinus thrombosis) in the first 15 days after administration of Johnson & Johnson’s COVID-19 vaccine,” one expert explained.

“We do not have a good explanation for this, but speculate that they may have additional/concomitant CVST risk factors (e.g., taking birth control pills) or a predisposition to autoantibody production that may have led to vaccine-associated thrombocytopenia with thrombosis,” he said.

Johnson & Johnson stopped once before

.

In April, Johnson & Johnson halted the launch of the vaccine after six cases of CVST were reported among recipients. Although the number of cases was small, top health officials advocated for a pause while the situation was assessed.

The problem was also seen with AstraZeneca’s vaccine. A handful of patients, including BBC presenter Lisa Shaw and British model Stephanie DuBois, died from blood clots after receiving AstraZeneca vaccines.

Another possible side effect

.

Johnson & Johnson’s COVID-19 vaccine has also been linked to a potentially increased risk of Guillain-Barré syndrome (GBS) after reports surfaced in July that about 100 people who received the vaccine in a single dose developed the disease. GBS is an autoimmune disease in which the immune system targets the nervous system. It can lead to muscle weakness or, in some cases, paralysis.

“Reports of adverse events following the use of Janssen COVID-19 vaccine under emergency approval indicate an increased risk of Guillain-Barré syndrome in the 42 days following vaccination,” the FDA said in an emergency approval fact sheet.

Beliebteste Artikel Aktuell: